Fortrea and SCRS Unite for Clinical Research Collaboration
Fortrea Partners with SCRS for Clinical Research Innovation
The Society for Clinical Research Sites (SCRS) and Fortrea (Nasdaq: FTRE), a prominent global contract research organization, have joined forces to advance the collaboration within the clinical research industry. This partnership is marked by Fortrea’s sponsorship of the SCRS Collaborate Forward working group, an initiative aimed at enhancing efficiency and reducing administrative burdens in clinical trial processes.
Collaborate Forward Working Group Objectives
This collaborative effort includes participation from 16 notable Global Impact Partner organizations. The primary goal of the Collaborate Forward working group is to develop and implement optimal practices that alleviate administrative challenges faced by clinical research sites. Through transparency and teamwork, the group intends to address ongoing obstacles in the clinical research framework, striving for sustainability and enhanced trial efficiency, ultimately benefiting patients.
Commitment to Innovation
Fortrea's support signifies a substantial commitment to innovation within the industry, affirming its belief that clinical research sites should lead the charge in trial planning. Mike Clay, senior vice president of Global Project Delivery at Fortrea, expressed enthusiasm for this partnership, emphasizing the importance of collaboration in facing the growing complexities of clinical trials. He noted, “By working closely with clinical research sites, we aim to unlock efficiencies and boost productivity, contributing to a more streamlined clinical trial process.”
Highlighting Successes
Scrutinizing and highlighting partnership successes, the Collaborate Forward initiative will also focus on sharing insights into improving processes and technology. As Sean Soth, senior vice president of Strategy and Global Business Partnerships at SCRS, pointed out, the initiative will showcase compelling stories and case studies that demonstrate the positive impact of collaboration in clinical research.
Improving Clinical Research Processes
The Collaborate Forward working group plans to convene regularly, facilitating discussions on industry trends while crafting practical tools for sponsors and CROs. By collaborating with various stakeholders, they aim to create a more efficient clinical trial ecosystem that benefits all constituents, including patients. Regular updates on the progress of this initiative will be shared to keep the industry informed about key achievements and insights obtained throughout the year.
Invitation to Join the Effort
SCRS encourages other sponsors and CROs committed to fostering site sustainability to engage in this initiative, facilitating the evolution of a more networked and responsive clinical research landscape. This collaboration invites everyone to contribute actively to the goals of improving the clinical research landscape.
About the Society for Clinical Research Sites
The Society for Clinical Research Sites serves as a leading advocacy organization, uniting the voice of the global clinical research site community. With representation from over 11,000 research sites worldwide, SCRS promotes industry advancements through advocacy, education, and connection. This organization plays a critical role in ensuring that the concerns and perspectives of clinical research sites are recognized and valued within broader industry initiatives.
About Fortrea
Fortrea, recognized as a leader in clinical development solutions, extends its expertise to various sectors within the life sciences industry. This organization partners with biopharmaceutical, biotechnology, medical device, and diagnostic companies, helping to accelerate the journey of innovative therapies to patients. With capabilities spanning clinical trial management and consulting functions, Fortrea operates in approximately 100 countries, driven by a commitment to impactful and high-quality healthcare solutions.
Frequently Asked Questions
What is the purpose of the Collaborate Forward working group?
The Collaborate Forward working group aims to develop best practices to reduce administrative burdens and enhance efficiency in clinical research.
Who are the main partners in this initiative?
The initiative primarily involves Fortrea and the Society for Clinical Research Sites, along with 16 Global Impact Partner organizations.
How does this collaboration benefit clinical research?
The collaboration fosters transparency and teamwork, improving trial efficiency and sustainability, ultimately benefiting patients participating in clinical trials.
What will be the focus of the working group initially?
The group will initially concentrate on study startup processes, sharing successful partnership stories and data-driven insights.
How can interested parties get involved?
Sponsors and CROs dedicated to site sustainability are encouraged to join this effort and contribute to the development of a more effective clinical research ecosystem.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.